Open AccessNew directions of research in the pharmacotherapy of Alzheimer’s disease
Author(s) -
Lucia Ţurcan,
AUTHOR_ID,
Anastasia Caracaş,
Dumitru Stirba,
Svelana Latus,
Olesea Malancea,
Nicolae Bacinschi,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2022
Publication title -
buletinul academiei de ştiinţe a moldovei: ştiinţe medicale
Language(s) - English
Resource type - Journals
ISSN - 1857-0011
DOI - 10.52692/1857-0011.2021.3-71.44
Subject(s) - life expectancy , disease , dementia , alzheimer's disease , medicine , pharmacotherapy , rivastigmine , quality of life (healthcare) , psychiatry , population , gerontology , psychology , donepezil , pathology , environmental health , nursing
Alzheimer’s disease, a neurodegenerative disease with a severe prognosis, accounts more than half of cases of dementia, associated with persistent and progressive memory loss, cognitive and personality disorders. According to the Alzheimer’s Association, in developed countries 13% of people over 65 years old suffer from Alzheimer’s disease, the fifth leading cause of death in patients of this age group. Data from the World Health Organization also shows that with the increase population and life expectancy, the overall incidence of Alzheimer’s disease will increase 4 times by 2050 and can reach 114 million. This will have a huge social impact and considerable economic burdens for the health system, as there are currently no efficient treatments for Alzheimer’s disease. The development of new, efficient and harmless drugs, designed to improve the quality and quantity of life of patients with Alzheimer’s disease remains a priority, and scientists globally combine their efforts to solve this problem. The etiopathogenetic links of Alzheimer’s disease are promising therapeutic targets for the discovery of efficient drug therapy.